Small Caps Squeeze 🚀 Biotech Breakout & Tesla’s Robotaxi Run

Government Shutdown, Crypto Uptick, and DIY Indexing with Public + Zero Hash

Welcome to Daily Rip Live with Katie Perry, Shay Boloor, and special co-host Jerremy Alexander Newsome as we dig into day one of Q4: government shutdown vibes, crypto momentum, spooky trade setups, and a hands-on tour of direct indexing with Public’s Head of Product Emily Kurtz—plus Zero Hash CEO Edward Woodford on why Wall Street is suddenly all-in on stablecoins and tokenization. This episode is brought to you by GraniteShares! Join Our Community! https://stocktwits.com/ [https://stocktwits.com/] Sign up for our daily FREE newsletter to keep in touch with the market: https://thedailyrip.stocktwits.com/ [https://thedailyrip.stocktwits.com/] Where to find the Daily Rip Live hosts on Stocktwits: Shay Boloor - https://stocktwits.com/ShayBoloor [https://stocktwits.com/ShayBoloor] Katie Perry - https://stocktwits.com/StocktwitsKP [https://stocktwits.com/StocktwitsKP] Jerremy Newsome - https://stocktwits.com/newsomenuggets [https://stocktwits.com/newsomenuggets] Edward Woodford - https://x.com/e_woodford [https://x.com/e_woodford] Disclaimer: All opinions expressed on this show are solely the opinions of the hosts’ and guests’ and do not reflect the opinions of Stocktwits, Inc. or its affiliates. The hosts are not SEC or FINRA registered advisors or professionals. The content of this show is for educational and entertainment purposes only. Please consult with your financial advisor before making any investment decision. Read the full terms & conditions here: https://stocktwits.com/about/legal/terms/ [https://stocktwits.com/about/legal/terms/]

Small Caps Squeeze 🚀 Biotech Breakout & Tesla’s Robotaxi Run

Jordan, Shay Boloor, and Michael Nauss, CMT dig into the week’s wild action: why small caps keep ripping despite record short interest, the CRISPR/biotech re-rating (and what just lit a fire under $NTLA), and how Tesla’s pivot to physical AI (robotaxi + Optimus + megapacks) could reset the narrative. We also hit stage-two AI winners (apps > infra), the “big base → high in space” playbook, 2026 cycle risks, and whether $OPEN’s story is more than a squeeze. Chapters 00:00 Intro & week recap (volatility, FOMC “nothing burger”) 01:10 Seasonality when above the 200-DMA; small caps at ATH with shorts piled on 02:24 What derails the uptrend? If anything, it’s geopolitical 05:00 Biotech rotation: CRISPR names ($CRSP $NTLA $BEAM $PRME) and M&A tailwinds 06:07 XBI anchored-VWAP breakout logic; winners vs junk in biotech 08:38 Why $NTLA’s phase 3 enrollment milestone mattered 11:41 AI stage two: from chips to software moats; who benefits 15:13 Valuations vs growth: $GOOGL, hyperscalers, and AI margin levers 17:02 Neo-clouds & power plays; Microsoft stamp-of-approval chatter 19:29 The “big base” strategy: $INTC, $BIDU, $ROKU, $PTON (and what not to chase) 21:45 $CVNA puzzle; when to just pass 22:35 $TTD patience vs proof 24:08 Nuclear momentum: $OKLO and the SMR trade (know your risk) 25:08 Macro cycle chat: why many have 2026 circled 29:18 How to invest through sideways markets (and keep boredom from killing you) 30:02 Index path vs micro bubbles; where pullbacks likely hit hardest 31:31 Palantir debate: growth re-accel, margins, and what the valuation implies ($PLTR) 42:49 Tesla deep-dive: robotaxi/Optimus, data + HW integration, grid monetization ($TSLA) 47:25 What would make Shay add more $TSLA; city-by-city rollout realities 50:04 Multiple super-cycles at once: AI, space, quantum, electrification 50:41 Meme & squeeze corner: $OPEN setup and pair-trade dynamics 56:12 The power of a “retail whisperer” and why storytelling matters 1:01:20 Raises/dilution in a forgiving tape; who should tap markets now 1:01:32 Redwire cautionary tale; why management quality is everything 1:02:57 Wrap & weekend send-off Tickers Mentioned (not advice): $IWM $IWC $XBI $CRSP $NTLA $BEAM $PRME $PLTR $NET $SNOW $MDB $ZS $GOOGL $MSFT $AMZN $OKLO $IONQ $INTC $BIDU $ROKU $PTON $CVNA $TTD $OPEN $QUBT $RDW Key Takeaways: * Shorts are maxed in small caps; dips likely get bought until a real blow-up forces covers. * Biotech/CRISPR is re-rating on data + M&A optionality; expect dispersion—know your science. * AI “stage two” = software moats and distribution, not just GPUs. * Tesla is increasingly a physical AI story (robotaxi + humanoids + energy), not “just cars.” * 2026 is a risk window; plan for chop even if the secular uptrend stays intact. If you learned something, smash 👍, subscribe, and catch us live next week. Trade safe!